Microbot Medical Inc. (NASDAQ:MBOT - Get Free Report) shares passed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $1.67 and traded as high as $2.67. Microbot Medical shares last traded at $2.54, with a volume of 1,310,034 shares.
Wall Street Analysts Forecast Growth
Separately, HC Wainwright reiterated a "buy" rating and issued a $9.00 price objective on shares of Microbot Medical in a report on Thursday, April 10th.
Get Our Latest Analysis on MBOT
Microbot Medical Stock Up 1.5%
The stock has a market cap of $98.22 million, a PE ratio of -3.37 and a beta of 1.15. The company has a fifty day moving average price of $2.18 and a 200 day moving average price of $1.72.
Microbot Medical (NASDAQ:MBOT - Get Free Report) last posted its earnings results on Wednesday, May 21st. The biotechnology company reported ($0.08) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.15) by $0.07. As a group, research analysts predict that Microbot Medical Inc. will post -0.71 earnings per share for the current year.
Institutional Trading of Microbot Medical
Several large investors have recently modified their holdings of MBOT. Geode Capital Management LLC grew its stake in shares of Microbot Medical by 7.9% in the fourth quarter. Geode Capital Management LLC now owns 142,659 shares of the biotechnology company's stock worth $160,000 after purchasing an additional 10,442 shares during the last quarter. Renaissance Technologies LLC bought a new stake in shares of Microbot Medical in the fourth quarter worth about $118,000. Virtu Financial LLC bought a new stake in shares of Microbot Medical in the first quarter worth about $42,000. Finally, Goldman Sachs Group Inc. bought a new stake in shares of Microbot Medical in the first quarter worth about $57,000. 16.30% of the stock is owned by institutional investors.
Microbot Medical Company Profile
(
Get Free Report)
Microbot Medical Inc, a pre-clinical medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company offers LIBERTY, an endovascular robotic surgical system which allows physicians to conduct a catheter-based procedure from outside the catheterization laboratory, and avoid radiation exposure, physical strain, and the risk of cross contamination for use in cardiovascular, peripheral, and neurovascular spaces.
Further Reading
Before you consider Microbot Medical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Microbot Medical wasn't on the list.
While Microbot Medical currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
